A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.,Journal of Clinical Psychopharmacology

当前位置： X-MOL 学术 › J. Clinical Psychopharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Journal of Clinical Psychopharmacology ( IF 2.9 ) Pub Date : 2021-6-29 , DOI: 10.1097/jcp.0000000000001404
Azmi Nasser ₁ , Tesfaye Liranso ₂ , Toyin Adewole ₁ , Nicholas Fry ₁ , Joseph T Hull ₁ , Gregory D Busse ₃ , Fatima Chowdhry ₁ , Andrew J Cutler ₄ , Nandita Joshi Jones ₅ , Robert L Findling ₆ , Stefan Schwabe ₇

Affiliation

This phase 3 clinical trial evaluated the efficacy and safety of viloxazine extended-release capsules (VLX-ER) as a monotherapy for attention-deficit/hyperactivity disorder (ADHD) in adolescents (12-17 years).

中文翻译：